Compounded semaglutide is made by a pharmacy to a prescriber’s order, not to an FDA label. That means there’s no official maximum dose for it. The only official ceilings belong to the approved semaglutide injections, Ozempic and Wegovy [2] [1]. Those are product-specific approved instructions rather than proof of a validated compounded regimen, and FDA has warned about compounded doses that go past them [3].
Compounded semaglutide has no official maximum because it has no label
A maximum dose is something FDA approves on a drug’s label, and compounded drugs do not have FDA-approved prescribing information for the pharmacy’s preparation. FDA says compounded drugs “are not FDA approved,” so the agency “does not review compounded drugs for safety, effectiveness or quality before they are marketed” [3].
A compounded preparation contains an ingredient identified as semaglutide, but its formulation and quality require separate assessment. The dosing comes from your prescriber. So when a program quotes a “max dose,” it’s quoting either the brand labels or its own protocol, and it’s worth asking which.
The two semaglutide injection labels set the reference points
The approved injection labels identify a 0.25 mg weekly initiation dose; those instructions do not establish a validated regimen for a pharmacy’s different preparation. Ozempic’s label maximum is 2 mg a week [2]. Wegovy’s label maximum is 7.2 mg a week, sold as Wegovy HD, but only for selected adult weight-management patients already tolerating 2.4 mg [1].
| Reference point | Wegovy injection | Ozempic |
|---|---|---|
| Labeled use | Weight management with age/form limits; adult cardiovascular and adult noncirrhotic MASH indications | Adult type 2 diabetes; established cardiovascular disease or chronic kidney disease for respective additional indications |
| Starting dose | 0.25 mg once weekly | 0.25 mg once weekly |
| Maintenance dose for weight | 1.7 mg or 2.4 mg (2.4 mg recommended) | Not approved for weight loss |
| Highest labeled injection dose | 7.2 mg for selected adult weight-management patients | 2 mg once weekly |
| Scope of the highest dose | Adult weight management, prior tolerability and additional clinical need; not the pediatric, cardiovascular or MASH maintenance instruction | Adult type 2 diabetes requiring additional glycemic control |
Milligrams once weekly, as labeled [1] [2]. Compounded products have no label; your prescriber sets the dose. The dose steps between start and maintenance are set by the label and your prescriber, and aren’t listed here.
Wegovy’s label maximum is 7.2 mg, with a trade-off
Wegovy’s usual maintenance dose for weight is 1.7 or 2.4 mg a week, and the label recommends 2.4 mg. For people who tolerate 2.4 mg for at least 4 weeks, the label says that when “additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly” [1].
The label identifies specific adverse-reaction differences in its adult higher-dose studies; that is not proof that every symptom rises monotonically with dose. Dysesthesia, an unusual or burning skin sensation, was reported by 22% of people on 7.2 mg, against 6% on 2.4 mg and 0.3% on placebo [1].
Wegovy is approved to lower the risk of heart attack, stroke and heart-related death in adults with established heart disease and obesity or overweight. It’s also approved for long-term weight management and, under accelerated approval, for noncirrhotic MASH with moderate to advanced fibrosis in adults [1]. More on the brand is on the Wegovy page.
Ozempic’s label maximum is 2 mg, for type 2 diabetes
Ozempic’s label says “the maximum recommended dosage is 2 mg once weekly” [2]. It’s approved to improve blood sugar in adults with type 2 diabetes, and to lower heart and kidney risks in adults with type 2 diabetes who have heart or kidney disease. It isn’t approved for weight loss, so a weight-loss program that quotes Ozempic’s 2 mg ceiling is borrowing a diabetes label.
FDA has seen problems with compounded doses above the label
FDA’s adverse-event files include reports possibly linked to compounded semaglutide or tirzepatide prescribed “in doses beyond what is in the FDA-approved drug label” [3]. The agency spells out what that means: “using more product in a single dose, taking doses more frequently or increasing the amount more quickly.”
Some of those events were serious, with people seeking medical help for stomach symptoms ranging from nausea to constipation [3]. FDA has separate reports, some requiring hospitalization, tied to dosing errors with compounded injectable semaglutide. Those errors came from patients measuring wrong doses and, in some cases, from clinicians miscalculating them.
Treatment response, tolerability and indication affect labeled dose selection
The relevant maintenance instructions differ by indication, age and formulation; a maximum number should not replace those distinctions. Wegovy’s label tells prescribers to “consider treatment response and tolerability when selecting the maintenance dosage” [1]. An exploratory 327-person STEP 1 extension without diabetes found about two-thirds of prior weight loss regained after both semaglutide 2.4 mg and lifestyle support stopped for a year [4].
That’s also why a compounded program’s dose list isn’t a menu. Your prescriber decides when, and whether, to change your dose. If side effects are hard to live with, raise it with them promptly; severe or persistent symptoms need clinical assessment rather than waiting for a scheduled dose review.
Questions to ask about your compounded dose
Ask your prescriber which evidence and formulation-specific considerations support the prescription, and have your pharmacist check the milligram dose on your vial’s label.
- What evidence supports this preparation and prescribed dose, and how does it differ from approved products?
- Is my dose, or my schedule for changing it, different from the label? If so, why?
- What dose in milligrams is printed on my vial’s label, and does it match my prescription?
- Which side effects should make me call before my next dose?
- When does my vial need to be thrown away?
The vial question matters because FDA advises discarding multi-dose vials 28 days after first use [3]; storage is covered in compounded semaglutide fridge rules. Doses below the label’s starting point are covered in microdosing GLP-1s. The tirzepatide version of the dose question is compounded tirzepatide starting dose. Risks are in is compounded semaglutide safe, and prices are in compounded semaglutide cost.